MonoSol must face states’ Suboxone complaint

Just two weeks after dismissing Reckitt Benckiser Healthcare from an antitrust lawsuit alleging it monopolised the production of its opioid treatment drug Suboxone, a federal judge in Pennsylvania ruled that co-defendant MonoSol must face the claims.

Get unlimited access to all Global Competition Review content